324 related articles for article (PubMed ID: 18390729)
21. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production.
Tobío A; Bandara G; Morris DA; Kim DK; O'Connell MP; Komarow HD; Carter MC; Smrz D; Metcalfe DD; Olivera A
Haematologica; 2020 Jan; 105(1):124-135. PubMed ID: 30948489
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
23. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
[TBL] [Abstract][Full Text] [Related]
24. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
[TBL] [Abstract][Full Text] [Related]
25. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
De Vita S; Schneider RK; Garcia M; Wood J; Gavillet M; Ebert BL; Gerbaulet A; Roers A; Levine RL; Mullally A; Williams DA
PLoS One; 2014; 9(5):e96209. PubMed ID: 24788138
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
Gabillot-Carré M; Lepelletier Y; Humbert M; de Sepuvelda P; Hamouda NB; Zappulla JP; Liblau R; Ribadeau-Dumas A; Machavoine F; Letard S; Baude C; Hermant A; Yang Y; Vargaftig J; Bodemer C; Morelon E; Lortholary O; Recher C; Laurent G; Dy M; Arock M; Dubreuil P; Hermine O
Blood; 2006 Aug; 108(3):1065-72. PubMed ID: 16597595
[TBL] [Abstract][Full Text] [Related]
27. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
28. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
29. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
30. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
Chan EC; Bai Y; Kirshenbaum AS; Fischer ER; Simakova O; Bandara G; Scott LM; Wisch LB; Cantave D; Carter MC; Lewis JC; Noel P; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
J Allergy Clin Immunol; 2014 Jul; 134(1):178-87. PubMed ID: 24582309
[TBL] [Abstract][Full Text] [Related]
31. CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
Greiner G; Witzeneder N; Berger A; Schmetterer K; Eisenwort G; Schiefer AI; Roos S; Popow-Kraupp T; Müllauer L; Zuber J; Sexl V; Kenner L; Sperr WR; Valent P; Mayerhofer M; Hoermann G
Blood; 2017 Jan; 129(3):371-382. PubMed ID: 27856463
[TBL] [Abstract][Full Text] [Related]
32. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
33. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood.
De Puysseleyr LP; Ebo DG; Elst J; Faber MA; Poorten MV; Van Gasse AL; Bridts CH; Mertens C; Van Houdt M; Hagendorens MM; Verlinden A; Vermeulen K; Maes MB; Berneman ZN; Sabato V
J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3176-3187.e3. PubMed ID: 33975032
[TBL] [Abstract][Full Text] [Related]
35. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
36. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
[TBL] [Abstract][Full Text] [Related]
37. The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
Taylor ML; Dastych J; Sehgal D; Sundstrom M; Nilsson G; Akin C; Mage RG; Metcalfe DD
Blood; 2001 Aug; 98(4):1195-9. PubMed ID: 11493470
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
Bibi S; Arock M
Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
